HOWL - Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors Stock Soars | Benzinga
Werewolf Therapeutics Inc (NASDAQ: HOWL) released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or metastatic solid tumors.
The preliminary data will be presented at the Society for Immunotherapy of Cancer's Annual Meeting.
The preliminary data include data collected as of October 18, 2023, from 16 heavily pretreated patients from the first four monotherapy dose escalation cohorts (1, 3, 6, 12 mg).
All treatment-emergent adverse events (TEAEs) were Grade 1 or ...